We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mechanism Explains How Resveratrol Reduces Upper Respiratory Inflammation

By LabMedica International staff writers
Posted on 12 Oct 2016
The red wine component resveratrol reduces inflammation in the upper respiratory tract by enhancing the activity of the protein MyD88 short, a negative regulator of inflammatory signaling pathways.

Resveratrol is found primarily in the skin and seeds of grapes. More...
The amount found in grape skins varies with the grape cultivar, its geographic origin, and exposure to fungal infection. The amount of fermentation time a wine spends in contact with grape skins is an important determinant of its resveratrol content. Epidemiological and experimental reports have linked mild-to-moderate wine and/or grape consumption to a lowered risk of cardiovascular, cerebrovascular, and peripheral vascular diseases.

The MyD88 (Myeloid differentiation primary response gene 88) gene encodes a cytosolic adapter protein that plays a central role in the innate and adaptive immune response. This protein functions as an essential signal transducer in the interleukin-1 and Toll-like receptor signaling pathways. These pathways regulate that activation of numerous pro-inflammatory genes. Patients with defects in this gene have an increased susceptibility to bacterial infections.

Upper respiratory tract inflammatory diseases such as asthma and chronic obstructive pulmonary diseases (COPD) affect more than 500 million people globally and are characterized by chronic inflammation that is often exacerbated by respiratory pathogens such as nontypeable Haemophilus influenzae (NTHi). The increasing numbers of antibiotic-resistant bacterial strains and the limited success of currently available pharmaceuticals used to manage the symptoms of these diseases present an urgent need for the development of novel anti-inflammatory therapeutic agents.

Investigators at Georgia State University (Atlanta, USA) reported in the September 28, 2016, online edition of the journal Scientific Reports that resveratrol decreased expression of pro-inflammatory mediators in airway epithelial cells and in the lungs of mice by enhancing NTHi-induced MyD88 short, a negative regulator of inflammation, via inhibition of ERK (Extracellular signal–regulated kinases) 1/2 activation. Furthermore, resveratrol inhibited NTHi-induced ERK1/2 phosphorylation by increasing MKP-1 (MAP kinase phosphatase) expression via a cAMP-PKA (Protein kinase A)-dependent signaling pathway. In addition, they showed that resveratrol had anti-inflammatory effects following NTHi infection, thereby demonstrating its therapeutic potential.

“We showed that an important component in red wine and also grapes called resveratrol can suppress inflammation,” said senior author Dr. Jian-Dong Li, director of the institute for biomedical sciences at Georgia State. “It has been shown that resveratrol can suppress inflammation, but how it regulates inflammation still remains largely unknown. We found that resveratrol suppresses a major bacterial pathogen causing otitis media and COPD by upregulating or increasing the production of a negative regulator called MyD88 short. The findings help us to shed light on developing new therapeutic strategies by targeting or pharmacologically upregulating MyD88 short production. We could use resveratrol to suppress inflammation or develop resveratrol derivatives that could be pharmacological agents to suppress inflammation using the same strategy.”

Related Links:
Georgia State University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.